24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Compugen
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
16:11
Sheryl Sandberg's harrowing documentary exposes Hamas sex crimes
17:56
Mobileye first quarter revenue falls by almost 50% as clients cut back on spending to clear excess stock
14:00
Melio names Boaz BenDavid as its first Chief Financial Officer
13:28
Check Point registers higher than expected Q1 profit helped by growth of AI-powered security platform
More stories
Buzz
Most popular
Daily
Weekly
1
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
2
Nvidia continues Israel shopping spree with acquisition of Deci
3
Nvidia announces $700 million acquisition of Run:ai
4
Nvidia on verge of completing $700 million acquisition of Run:ai
5
Sheryl Sandberg's harrowing documentary exposes Hamas sex crimes
More news
Compugen
5 stories about Compugen
Compugen shares soar on massive deal with Gilead, worth up to $848 million
19.12.23
|
Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
Compugen Falls 17% on Employee Cuts Announcement
27.02.19
|
Lilach Baumer
The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday
Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen
12.10.18
|
Dror Reich
The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb
Biotech Company Compugen Down on Nasdaq Following $21 Million Direct Offering
17.06.18
|
Dror Reich
The Israel-based cancer immunotherapy company intends to use the proceedings for product development
AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen
03.04.18
|
Lilach Baumer
The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen
Please ensure Javascript is enabled for purposes of
website accessibility